Browsing Tag
Organon & Co.
4 posts
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
Is Organon giving up on medtech? Why its $465m JADA exit could reshape the postpartum hemorrhage market
Organon sells JADA System to Laborie for up to $465M. Learn how this reshapes Organon’s focus and expands Laborie’s maternal health portfolio.
PTC Therapeutics, TG Therapeutics, and Zimmer Biomet among top U.S. stock losers
See which U.S. stocks fell the most on May 5, 2025, and why—an in-depth look at the market’s biggest losers amid trade tensions and sector-specific headwinds.
Wall Street rout: Top U.S. stock losers on May 1 reflect deep-sector woes, policy shocks, and earnings misses
Discover how major U.S. companies like Eli Lilly and Becton Dickinson are navigating stock declines amid economic and industry challenges.